United States Heartworm Treatment Market -2024-2031

United States Heartworm Treatment Market -2024-2031

United States Heartworm Treatment Market reached US$ YY billion in 2023 and is expected to reach US$ YY million by 2031 growing at a CAGR of YY% during the forecast period 2024-2031.

Heartworm disease is a fatal infection caused by a worm parasite called Dirofilaria immitis. It is spread from the host through the bites of mosquitoes and mainly occurs in dogs, cats, ferrets, and wolves. Blood tests that identify the presence of circulating microfilariae or antigens made by adult female heartworms can be used to diagnose heartworm illness.

Heartworm disease can cause serious health complications including damage to the heart, lungs, and other organs. The objectives of treating heartworm disease are to get rid of the parasite infection, lessen symptoms, and extend the life of the animal companion.

Market Dynamics

Increasing advancements in veterinary medicines

The increasing advancements in veterinary medicines act as a significant driver for market growth. The creation of highly effective preventive drugs is one of the biggest developments in the treatment of heartworm disease. These drugs, which come in many forms like injectables, topical treatments, and oral tablets, have active chemicals that destroy heartworm larvae (microfilariae) and stop infected pets from developing adult heartworms.

Also, minimally invasive treatment techniques, such as laparoscopic-assisted extraction show an alternative to conventional surgical methods. These methods expedite the recuperation process for impacted animals, lessen surgical trauma, and limit postoperative problems.

For instance, in April 2023, the U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's newest addition to its feline portfolio NexGard COMBO (esafoxolaner, eprinomectin, and praziquantel topical solution).

Furthermore, significant growth drivers such as the increasing awareness and campaigns regarding heartworms and pet health expenditure are expected to drive the market in the forecast period.

Limited treatment options

Medication licensed for the treatment of heartworm disease in pets is quite limited. There is only one FDA-approved medication that can eradicate adult canine heartworms called melarsomine dihydrochloride. Also, treatment success rates can vary depending on factors such as the stage of the disease, the number of adult worms present, and the pet's overall health status. Thus, the above factors can hamper the market growth.

For more details on this report – Request for Sample

Segment Analysis

The United States heartworm treatment market is segmented based on animal type, product type and distribution channel.

The oral tablets segment accounted for approximately 45.3% of the market share

The oral tablets segment is expected to hold the largest market share over the period forecast. Oral tablets containing ivermectin are often prescribed as a preventive measure to protect dogs from heartworm infection. To provide broad-spectrum defense against intestinal parasites, fleas, ticks, and heartworms, some oral tablets blend many active components. These combination medications frequently include praziquantel (for tapeworms), milbemycin oxime, and ivermectin as components.

Veterinarians are essential in identifying heartworm disease, recommending suitable drugs, and creating a thorough treatment regimen customized to each pet’s requirements. For instance, in July 2023, Boehringer Ingelheim Received FDA Approval for NexGard PLUS (afoxolaner, moxidectin and pyrantel chewable tablets) that protects against fleas, ticks, heartworm disease, roundworms and hookworms.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the United States heartworm treatment market. The pandemic disrupted global supply chains, leading to shortages and delays in the availability of veterinary medications and diagnostic tests for heartworm preventives. Veterinary clinics have faced difficulties finding and restocking heartworm prevention drugs, which has affected their capacity to offer pets continuous treatment. Therefore, owing to the above factors, the heartworm treatment market was moderately affected over the forecast period.

Market Segmentation

By Animal Type
• Dogs
• Cats
• Ferrets
• Others

By Product Type
• Injections
• Oral tablets
• Powders
• Sprays
• Others

By Distribution Channel
• Veterinary Clinics
• Online sales
• Others

Competitive Landscape

The major players in the market include Zoetis Services LLC., Boehringer Ingelheim Animal Health USA Inc., Midas Pharma Inc., Ceva Animal Health LLC, Elanco, Merck & Co.Inc (Merck Animal Health USA), Advacare Pharma, Virbac, Bayer AG, Pfizer Inc. among others.

Why Purchase the Report?
• To visualize the United States heartworm treatment market segmentation based on animal type, product type, and distribution channel as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of United States heartworm treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The United States heartworm treatment market report would provide approximately 38 tables, 28 figures, and 185 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies